Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xemilofiban SCHEMBL50663 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL609244 | 0.99 | ITGB3 (0.98) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| Xemilofiban SCHEMBL27987260 | 0.98 | ITGB3 (0.96) | ITGB3ITGA2B | |
| SCHEMBL7351416 | 0.90 | ITGB3 (0.81) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7353828 | 0.87 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7346572 | 0.87 | ITGB3 (0.77) | ITGB3ITGA2BLMNAMAPTTDP1 | |
| SCHEMBL7346651 | 0.86 | ITGB3 (0.77) | ITGB3ITGA2B | |
| SCHEMBL7348945 | 0.86 | ITGB3 (0.75) | ITGB3ITGA2B | |
| SCHEMBL7355439 | 0.85 | ITGB3 (0.79) | ITGB3ITGA2B | |
| SCHEMBL7346593 | 0.85 | ITGB3 (0.74) | ITGB3ITGA2BLMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-0946178-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO INC (US) | 2003-05-07 | — | — | EP | claimed |
| EP-0939900-A4 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020009753-A1 | Anticoagulant test | BEDNAR BOHUMIL (US) | 2002-01-24 | — | — | US | claimed |
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | GOULD ROBERT J (US) | 2001-11-01 | — | — | US | claimed |
| EP-0542708-B1 | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2001-05-30 | — | — | EP | claimed |
| US-6235706-B1 | Combination therapy for reducing the risks associated with cardiovascular disease | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| US-6210904-B1 | DIAGNOSING FOR RISK OF THROMOCYTOPENIA BY DETECTING ABSENCE OF ASSOCIATION OF MONOCLONAL ANTIBODY WITH GLYCOPROTEIN IIB/IIA RECEPTOR:GLYCOPROTEIN IIB/IIA RECEPTOR ANTAGONIST COMPLEX | MERCK & CO., INC. | 2001-04-03 | — | — | US | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997035615-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | claimed |
| US-5344957-A | Amidinoiphenyl-substituted | G.D. SEARLE & CO. (US) | 1994-09-06 | — | — | US | claimed |
| EP-0542708-A1 | Substituted B-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-05-19 | — | — | EP | claimed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036913-A1 | Combination therapy for reducing the risks associated with cardiovascular disease | HMGCR, PCSK9, APOB | ITGB3 699/4885ITGA2B 740/4885LMNA 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.